Efficacy and safety of zenagamtide s.c. once weekly compared to semaglutide s.c. once weekly at lower dose levels in participants with type 2 diabetes inadequately controlled on metformin, SGLT2i, or both (AMBITION 4)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525474-20-00

Enrollment

Registered

2026-10-21

Start date

Unknown

Completion date

Unknown

Last updated

2026-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Participants with type 2 diabetes

Brief summary

Change in glycated haemoglobin A1c (HbA1c)

Detailed description

Relative change in body weight, Change in triglycerides, Change in waist circumference

Interventions

DRUGsemaglutide K 10095

DRUGNNC0487-0111 B 10141

DRUGsemaglutide K 10096

DRUGsemaglutide K 10088

DRUGNNC0487-0111 B 10142

DRUGNNC0487-0111 B 10144

DRUGPlacebo (Zenagamtide)

DRUGPlacebo (semaglutide)

DRUGNNC0487-0111 B 10143

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in glycated haemoglobin A1c (HbA1c)	—

Secondary

Measure	Time frame
Relative change in body weight, Change in triglycerides, Change in waist circumference	—

Outcome results

None listed

Source: EU CTIS · Data processed: Oct 23, 2026